- Text-only version of this website
- Skip navigation
- Home page
- What's new
- Contact Webmaster
- Website policies
- Disability services
The Boye Lab1
AAV: a beautiful and powerful virus2
Dr. Boye and her Genzyme/Sanofi colleagues working together to treat a form of childhood blindness3
Our Research Focus
- to develop AAV-based gene therapy approaches for delivering genes to the outer retina (notably foveal cones) following intravitreal delivery
- to develop an AAV-based gene therapy for treatment of GUCY2D-Leber congenital amaurosis-1 (LCA1)
- to develop dual AAV vector platforms that are capable of delivering large transgenes (> 5kb)
- to develop gene replacement therapies for various forms of Congenital Stationary Night Blindness (CSNB), a disorder caused by mutations in genes which express bipolar cell- specific proteins.
On October 23rd, Miranda White passed her qualifying exam and officially became a ‘doctoral candidate’. Congratulations!
The collaborative efforts between Dr. Boye and Genzyme to develop a gene therapy for GUCY2D LCA1 were recently featured in a press release. A link to the aritcle can be found […]
The team is happy to welcome its two newest members. In August, postdoctoral associate Shreyasi Choudhury, Ph.D. and laboratory assistant Tyler McCullough, M.S. joined the group. They bring with them valuable experience […]
“High Resolution Transcriptomics: Dissecting the Molecular Program Underlying Retinal Development”- Rahul Kanadia
DECEMBER 5th!!! Here we come Denver!
Presented by the Center for Vision Research and Institute on Aging “Mitochondrial Function and Metabolism in Aging and Vision” McKnight Brain Institute DeWeese Auditorium (LG-101A) December 8, 2014, 8:00-5:00